← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #1352 OF 1,916 MOST-CITED

Annual report

FDA cited this observation 10 times across 10 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

What this grouping is not

An observation-type page groups FDA’s published citation records. The grouping, the compliance steps and the root causes are SPEQ synthesis, not an FDA classification of any citation, and a count measures what FDA published rather than risk.

BY PROGRAM AREA
Bioresearch Monitoring10
BY FISCAL YEAR
FY20261
FY20252
FY20242
FY20233
FY20221
FY20161

How FDA worded it — real examples

Failure to submit to FDA within 60 days of the anniversary date that the IND went into effect an annual report of the investigation.

John N. Allan, M.D. · New York, New York · Bioresearch Monitoring · 2026-06-22

Failure to submit to FDA within 60 days of the anniversary date that the IND went into effect an annual report of the investigation.

Jose D. Gutierrez, MD, MPH · New York, New York · Bioresearch Monitoring · 2025-01-10

Failure to submit to FDA within 60 days of the anniversary date that the IND went into effect an annual report of the investigation.

Christopher S. Stauffer, M.D. · Vancouver, Washington · Bioresearch Monitoring · 2024-12-03

Failure to submit to FDA an annual report of the investigation.

Alexander Khoruts, M.D., Sponsor-Investigator · Minneapolis, Minnesota · Bioresearch Monitoring · 2024-08-26

Failure to submit to FDA an annual report of the investigation.

Leslie H. Lundahl, PhD · Detroit, Michigan · Bioresearch Monitoring · 2023-12-15

Failure to submit to FDA an annual report of the investigation.

R. Doyle Stulting, MD · Atlanta, Georgia · Bioresearch Monitoring · 2023-08-18

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

GCP discipline

Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →